ascendis pharma glp-1 receptor agonists weight management diabetes treatments are transforming care by improving blood sugar control, supporting loss, and reducing cardiovascular risk when used appropriately. Evidence-based therapy selection, correct dosing, and patient counseling are GLP1 Receptor Agonists—Effects beyond Obesity

All strengths will be available from the manufacturer as the shortage has ended, but after April 22, 2025, compounding pharmacies will be only able to make custom doses

is an employee and stockholder of Sosei Heptares

doi: 10.1016/j.physbeh.2015.06.013 189 SteinbergE

As only one patient with IIH-WOP was treated with a GLP-1-RA, this was insufficient to conduct subgroup analyses, so we could only perform sensitivity analyses removing IIH-WOP patients to exclude potential confounding effect on our results

IQVIA analysis of more than 14,000 ChannelDynamics recorded promotional interactions across EU4, UK and US suggest that messaging is already moving away from basics about the availability of a new approach to weight loss, and towards labelled benefits and supporting evidence